Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017 (2017), Article ID 1741386, 8 pages
https://doi.org/10.1155/2017/1741386
Research Article

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence should be addressed to Peiquan Zhao

Received 13 December 2016; Revised 7 February 2017; Accepted 5 March 2017; Published 29 March 2017

Academic Editor: Thomas Bertelmann

Copyright © 2017 Qiujing Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Early Treatment For Retinopathy Of Prematurity Cooperative Group, “Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial,” Archives of Ophthalmology, vol. 121, no. 12, pp. 1684–1694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Alon, I. Hemo, A. Itin, J. Pe'er, J. Stone, and E. Keshet, “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity,” Nature Medicine, vol. 1, no. 10, pp. 1024–1028, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. M. E. Hartnett and J. S. Penn, “Mechanisms and management of retinopathy of prematurity,” The New England Journal of Medicine, vol. 367, no. 26, pp. 2515–2526, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Mataftsi, S. Dimitrakos, and G. Adams, “Mediators involved in retinopathy of prematurity and emerging therapeutic targets,” Early Human Development, vol. 87, no. 10, pp. 683–690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Mintz-Hittner, K. A. Kennedy, A. Z. Chuang, and BEAT-ROP Cooperative Group, “Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity,” The New England Journal of Medicine, vol. 364, no. 7, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. R. K. Wong, S. Hubschman, and I. Tsui, “Reactivation of retinopathy of prematurity after ranibizumab treatment,” Retina, vol. 35, no. 4, pp. 675–680, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. J. Lee, J. H. Kim, H. Heo, and Y. S. Yu, “Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity,” Eye, vol. 26, no. 7, pp. 903–910, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Y. Jang, K. S. Choi, and S. J. Lee, “Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity,” Journal of AAPOS, vol. 14, no. 5, pp. 457–459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. Ocular Fundus Disease Group of Chinese Ophthalmology, “The Chinese screening guide of retinopathy of prematurity (2015),” Chinese Journal of Ophthalmology, vol. 50, pp. 933–935, 2014. View at Google Scholar
  10. M. P. Blair, “Reactivation of retinopathy of prematurity after bevacizumab injection,” Archives of Ophthalmology, vol. 130, no. 8, p. 1000, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Stahl, A. Hellstrom, and L. E. H. Smith, “Insulin-like growth factor-1 and anti-vascular endothelial growth factor in retinopathy of prematurity: has the time come,” Neonatology, vol. 106, no. 3, pp. 254–260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. W. C. Wu, H. K. Kuo, P. T. Yeh, C. M. Yang, C. C. Lai, and S. N. Chen, “An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan,” American Journal of Ophthalmology, vol. 155, no. 1, pp. 150–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. T. U. Krohne, Z. Liu, F. G. Holz, and C. H. Meyer, “Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans,” American Journal of Ophthalmology, vol. 154, no. 4, pp. 682–686.e2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Bakri, M. R. Snyder, J. M. Reid, J. S. Pulido, M. K. Ezzat, and R. J. Singh, “Pharmacokinetics of intravitreal ranibizumab (Lucentis),” Ophthalmology, vol. 114, no. 12, pp. 2179–2182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. L. Hård and A. Hellström, “On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment - a review,” Acta Paediatrica, vol. 100, no. 12, pp. 1523–1527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Tolentino, “Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease,” Survey of Ophthalmology, vol. 56, no. 2, pp. 95–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Zhang, M. Yang, J. Zeng et al., “Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity,” Retina, Published Online First: 12 August 2016 View at Publisher · View at Google Scholar · View at Scopus
  18. H. A. Mintz-Hittner, M. M. Geloneck, and A. Z. Chuang, “Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy,” Ophthalmology, vol. 123, no. 9, pp. 1845–1855, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. H. A. Mintz-Hittner, “Avastin as monotherapy for retinopathy of prematurity,” Journal of AAPOS, vol. 14, no. 1, pp. 2–3, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. A. Darlow, A. L. Ells, C. E. Gilbert, G. A. Gole, and G. E. Quinn, “Are we there yet? Bevacizumab therapy for retinopathy of prematurity,” Archives of Disease in Childhood. Fetal and Neonatal Edition, vol. 98, no. 2, pp. F170–F174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Honda, H. Hirabayashi, Y. Tsukahara, and A. Negi, “Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 7, pp. 1061–1063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Klaassen, R. J. van Geest, E. J. Kuiper, C. J. van Noorden, and R. O. Schlingemann, “The role of CTGF in diabetic retinopathy,” Experimental Eye Research, vol. 133, pp. 37–48, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. L. C. Zepeda-Romero, J. A. Liera-Garcia, J. A. Gutiérrez-Padilla, C. I. Valtierra-Santiago, and C. D. Avila-Gómez, “Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity,” Eye (London, England), vol. 24, no. 5, pp. 931–933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. W. C. Wu, P. T. Yeh, S. N. Chen, C. M. Yang, C. C. Lai, and H. K. Kuo, “Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan,” Ophthalmology, vol. 118, no. 1, pp. 176–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. E. A. Palmer, “Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP),” Documenta Ophthalmologica, vol. 74, no. 3, pp. 245–251, 1990. View at Publisher · View at Google Scholar · View at Scopus